Hepatitis C, A Global Issue: Access to Care and New Therapeutic and Preventive Approaches in Resource-Constrained Areas

 

 Permissions and Reprints

Abstract

With the advent of all oral direct-acting antiviral drugs with a broad range of genotypic activity and a low incidence of side effects, we are entering an exciting new era in the therapeutics of hepatitis C virus (HCV). However, it is not yet clear who will benefit from these innovations: Will the advantages be limited to HCV patients in industrialized nations or could the whole community of HCV-infected individuals be given access to treatment? As the majority of people infected with HCV live in resource-limited settings it is important to overcome the barriers that restrict access to treatment in these areas. Drug costs, public and professional education, simplified diagnostics, and political imperative all need to be addressed before the majority of HCV-infected individuals can benefit from the new generation of HCV antivirals.

• References

• 1 Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57 (4) 1333-1342
  CrossrefPubMedGoogle Scholar
• 2 Wantuck JM, Ahmed A, Nguyen MH. Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6. Aliment Pharmacol Ther 2014; 39 (2) 137-147
  CrossrefPubMedGoogle Scholar
• 3 Thursz M, Fontanet A. HCV transmission in industrialized countries and resource-constrained areas. Nat Rev Gastroenterol Hepatol 2014; 11 (1) 28-35
  PubMedGoogle Scholar
• 4 Lozano R, Naghavi M, Foreman K , et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380 (9859) 2095-2128
  CrossrefPubMedGoogle Scholar
• 5 Lemoine M, Thursz M, Njie R, Dusheiko G. Forgotten, not neglected: viral hepatitis in resource-limited settings, recall for action. Liver Int 2014; 34 (1) 12-15
  CrossrefPubMedGoogle Scholar
• 6 Cooke GS, Lemoine M, Thursz M , et al. Viral hepatitis and the Global Burden of Disease: a need to regroup. J Viral Hepat 2013; 20 (9) 600-601
  CrossrefPubMedGoogle Scholar
• 7 Sievert W, Altraif I, Razavi HA , et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011; 31 (Suppl. 02) 61-80
  CrossrefPubMedGoogle Scholar
• 8 Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999; 6 (1) 35-47
  CrossrefPubMedGoogle Scholar
• 9 Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5 (9) 558-567
  CrossrefPubMedGoogle Scholar
• 10 Nguyen LH, Nguyen MH. Systematic review: Asian patients with chronic hepatitis C infection. Aliment Pharmacol Ther 2013; 37 (10) 921-936
  CrossrefPubMedGoogle Scholar
• 11 Pham DA, Leuangwutiwong P, Jittmittraphap A , et al. High prevalence of Hepatitis C virus genotype 6 in Vietnam. Asian Pac J Allergy Immunol 2009; 27 (2-3) 153-160
  PubMedGoogle Scholar
• 12 Thu Thuy PT, Bunchorntavakul C, Tan Dat H, Rajender Reddy K. A randomized trial of 48 versus 24 weeks of combination pegylated interferon and ribavirin therapy in genotype 6 chronic hepatitis C. J Hepatol 2012; 56 (5) 1012-1018
  CrossrefPubMedGoogle Scholar
• 13 Guerra J, Garenne M, Mohamed MK, Fontanet A. HCV burden of infection in Egypt: results from a nationwide survey. J Viral Hepat 2012; 19 (8) 560-567
  CrossrefPubMedGoogle Scholar
• 14 Frank C, Mohamed MK, Strickland GT , et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000; 355 (9207) 887-891
  CrossrefPubMedGoogle Scholar
• 15 Lehman EM, Wilson ML. Epidemic hepatitis C virus infection in Egypt: estimates of past incidence and future morbidity and mortality. J Viral Hepat 2009; 16 (9) 650-658
  CrossrefPubMedGoogle Scholar
• 16 Hope VD, Eramova I, Capurro D, Donoghoe MC. Prevalence and estimation of hepatitis B and C infections in the WHO European Region: a review of data focusing on the countries outside the European Union and the European Free Trade Association. Epidemiol Infect 2014; 142 (2) 270-286
  CrossrefPubMedGoogle Scholar
• 17 Hatzakis A, Van Damme P, Alcorn K , et al. The state of hepatitis B and C in the Mediterranean and Balkan countries: report from a summit conference. J Viral Hepat 2013; 20 (Suppl. 02) 1-20
  PubMedGoogle Scholar
• 18 Payan C, Roudot-Thoraval F, Marcellin P , et al. Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study. J Viral Hepat 2005; 12 (4) 405-413
  CrossrefPubMedGoogle Scholar
• 19 Ansaldi F, Bruzzone B, Salmaso S , et al. Different seroprevalence and molecular epidemiology patterns of hepatitis C virus infection in Italy. J Med Virol 2005; 76 (3) 327-332
  CrossrefPubMedGoogle Scholar
• 20 Katsoulidou A, Sypsa V, Tassopoulos NC , et al. Molecular epidemiology of hepatitis C virus (HCV) in Greece: temporal trends in HCV genotype-specific incidence and molecular characterization of genotype 4 isolates. J Viral Hepat 2006; 13 (1) 19-27
  CrossrefPubMedGoogle Scholar
• 21 Medrano J, Resino S, Vispo E , et al. Hepatitis C virus (HCV) treatment uptake and changes in the prevalence of HCV genotypes in HIV/HCV-coinfected patients. J Viral Hepat 2011; 18 (5) 325-330
  CrossrefPubMedGoogle Scholar
• 22 Kershenobich D, Razavi HA, Sánchez-Avila JF , et al. Trends and projections of hepatitis C virus epidemiology in Latin America. Liver Int 2011; 31 (Suppl. 02) 18-29
  PubMedGoogle Scholar
• 23 Karoney MJ, Siika AM. Hepatitis C virus (HCV) infection in Africa: a review. Pan Afr Med J 2013; 14: 44
  PubMedGoogle Scholar
• 24 Madhava V, Burgess C, Drucker E. Epidemiology of chronic hepatitis C virus infection in sub-Saharan Africa. Lancet Infect Dis 2002; 2 (5) 293-302
  CrossrefPubMedGoogle Scholar
• 25 Markov PV, Pepin J, Frost E, Deslandes S, Labbé AC, Pybus OG. Phylogeography and molecular epidemiology of hepatitis C virus genotype 2 in Africa. J Gen Virol 2009; 90 (Pt 9) 2086-2096
  CrossrefPubMedGoogle Scholar
• 26 Njouom R, Caron M, Besson G , et al. Phylogeography, risk factors and genetic history of hepatitis C virus in Gabon, central Africa. PLoS ONE 2012; 7 (8) e42002
  CrossrefPubMedGoogle Scholar
• 27 Njouom R, Frost E, Deslandes S , et al. Predominance of hepatitis C virus genotype 4 infection and rapid transmission between 1935 and 1965 in the Central African Republic. J Gen Virol 2009; 90 (Pt 10) 2452-2456
  CrossrefPubMedGoogle Scholar
• 28 Antaki N, Abboud D, Antaki F, Craxi A. HCV genotype 5: an orphan virus. Antivir Ther 2013; 18 (3) 263-269
  PubMedGoogle Scholar
• 29 Xia YH, Chen W, Tucker JD, Wang C, Ling L. HIV and hepatitis C virus test uptake at methadone clinics in Southern China: opportunities for expanding detection of bloodborne infections. BMC Public Health 2013; 13: 899
  CrossrefPubMedGoogle Scholar
• 30 Quan VM, Go VF, Nam V , et al. Risks for HIV, HBV, and HCV infections among male injection drug users in northern Vietnam: a case-control study. AIDS Care 2009; 21 (1) 7-16
  CrossrefPubMedGoogle Scholar
• 31 Nelson PK, Mathers BM, Cowie B , et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011; 378 (9791) 571-583
  CrossrefPubMedGoogle Scholar
• 32 Rockstroh JK, Mocroft A, Soriano V , et al; EuroSIDA Study Group. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005; 192 (6) 992-1002
  CrossrefPubMedGoogle Scholar
• 33 Barth RE, Huijgen Q, Taljaard J, Hoepelman AI. Hepatitis B/C and HIV in sub-Saharan Africa: an association between highly prevalent infectious diseases. A systematic review and meta-analysis. Int J Infect Dis 2010; 14 (12) e1024-e1031
  CrossrefPubMedGoogle Scholar
• 34 Ladep NG, Agaba PA, Agbaji O , et al. Rates and impact of hepatitis on human immunodeficiency virus infection in a large African cohort. World J Gastroenterol 2013; 19 (10) 1602-1610
  CrossrefPubMedGoogle Scholar
• 35 Laurent C, Bourgeois A, Mpoudi-Ngolé E , et al. High rates of active hepatitis B and C co-infections in HIV-1 infected Cameroonian adults initiating antiretroviral therapy. HIV Med 2010; 11 (1) 85-89
  CrossrefPubMedGoogle Scholar
• 36 Bowring AL, Luhmann N, Pont S , et al. An urgent need to scale-up injecting drug harm reduction services in Tanzania: prevalence of blood-borne viruses among drug users in Temeke District, Dar-es-Salaam, 2011. Int J Drug Policy 2013; 24 (1) 78-81
  CrossrefPubMedGoogle Scholar
• 37 Raguin G, Lepretre A, Ba I , et al. Drug use and HIV in West Africa: a neglected epidemic. Trop Med Int Health 2011; 16 (9) 1131-1133
  CrossrefPubMedGoogle Scholar
• 38 Joshi D, O'Grady J, Dieterich D, Gazzard B, Agarwal K. Increasing burden of liver disease in patients with HIV infection. Lancet 2011; 377 (9772) 1198-1209
  CrossrefPubMedGoogle Scholar
• 39 Salmon-Ceron D, Rosenthal E, Lewden C , et al; ANRS EN19 Mortalité Study Group and Mortavic. Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: The French national Mortalité 2005 study. J Hepatol 2009; 50 (4) 736-745
  CrossrefPubMedGoogle Scholar
• 40 Dodd RY, Notari IV EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002; 42 (8) 975-979
  CrossrefPubMedGoogle Scholar
• 41 Hauri AM, Armstrong GL, Hutin YJ. The global burden of disease attributable to contaminated injections given in health care settings. Int J STD AIDS 2004; 15 (1) 7-16
  CrossrefPubMedGoogle Scholar
• 42 Pépin J, Lavoie M, Pybus OG , et al. Risk factors for hepatitis C virus transmission in colonial Cameroon. Clin Infect Dis 2010; 51 (7) 768-776
  CrossrefPubMedGoogle Scholar
• 43 Kandeel AM, Talaat M, Afifi SA , et al. Case control study to identify risk factors for acute hepatitis C virus infection in Egypt. BMC Infect Dis 2012; 12: 294
  CrossrefPubMedGoogle Scholar
• 44 Chlabicz S, Grzeszczuk A, Prokopowicz D. Medical procedures and the risk of iatrogenic hepatitis C infection: case-controlled study in north-eastern Poland. J Hosp Infect 2004; 58 (3) 204-209
  CrossrefPubMedGoogle Scholar
• 45 Safi SZ, Waheed Y, Sadat J , et al. Molecular study of HCV detection, genotypes and their routes of transmission in North West Frontier Province, Pakistan. Asian Pac J Trop Biomed 2012; 2 (7) 532-536
  CrossrefPubMedGoogle Scholar
• 46 Lemoine M, Nayagam S, Thursz M. Viral hepatitis in resource-limited countries and access to antiviral therapies: current and future challenges. Future Virol 2013; 8 (4) 371-380
  CrossrefPubMedGoogle Scholar
• 47 World Hepatitis Alliance Available at: http://www.who.int/immunization/topics/hepatitis_b_survey_2010/en/ . Accessed January 5, 2014
  PubMed
• 48 Hatzakis A, Wait S, Bruix J , et al. The state of hepatitis B and C in Europe: report from the Hepatitis B and C Summit Conference*. J Viral Hepat 2011; 18 (Suppl. 01) 1-16
  PubMedGoogle Scholar
• 49 Thomas DL. Curing hepatitis C with pills: a step toward global control. Lancet 2010; 376 (9751) 1441-1442
  CrossrefPubMedGoogle Scholar
• 50 World Health Organization Available at: http://www.who.int/csr/disease/hepatitis/global_report/en/index.html . Accessed January 7, 2014
  PubMed
• 51 Centers for Disease Control and Prevention (CDC). Progress toward prevention and control of hepatitis C virus infection—Egypt, 2001-2012. MMWR Morb Mortal Wkly Rep 2012; 61 (29) 545-549
  PubMedGoogle Scholar
• 52 Eurasian harm reduction network (EHRN) 2013. Available at: http://www.idhdp.com/media/33100/ehrn_hepatitis_c_treatment_access_in_eeca.pdf . Accessed January 5, 2014
  PubMedGoogle Scholar
• 53 Marseille E, Hofmann PB, Kahn JG. HIV prevention before HAART in sub-Saharan Africa. Lancet 2002; 359 (9320) 1851-1856
  CrossrefPubMedGoogle Scholar
• 54 UNAIDS. Guidelines for 2014 Global AIDS response progress reporting. Available at: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120_UNAIDS_Global_Report_2012_en.pdf . Accessed January 6, 2014
  PubMedGoogle Scholar
• 55 WTO. The Doha declaration explained. Available at: http://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_trips_e.pdf . Accessed January 6, 2014
  PubMedGoogle Scholar
• 56 Hill A. Minimum costs to provide hepatitis C direct acting antivirals. Available at: http://freepdfhosting.com/d4a7e2bba6.pdf . Accessed January 7, 2014
  PubMedGoogle Scholar
• 57 Medicines Patent Pool. Advancing innovation, access, and public health. Available at: http://www.medicinespatentpool.org . Accessed January 7, 2014
  PubMedGoogle Scholar
• 58 Ford N, Singh K, Cooke GS , et al. Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV/AIDS. Clin Infect Dis 2012; 54 (10) 1465-1472
  CrossrefPubMedGoogle Scholar
• 59 Bouvier-Alias M, Patel K, Dahari H , et al. Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication. Hepatology 2002; 36 (1) 211-218
  CrossrefPubMedGoogle Scholar
• 60 WHO. Prevention and control of viral hepatitis infection: framework for global action. Available at: http://www.who.int/csr/disease/hepatitis/GHP_framework.pdf . Accessed January 6, 2014
  PubMedGoogle Scholar
• 61 Edlin BR. Perspective: test and treat this silent killer. Nature 2011; 474 (7350) S18-S19
  PubMedGoogle Scholar
• 62 Hagan LM, Wolpe PR, Schinazi RF. Treatment as prevention and cure towards global eradication of hepatitis C virus. Trends Microbiol 2013; 21 (12) 625-633
  CrossrefPubMedGoogle Scholar
• 63 Hagan LM, Schinazi RF. Best strategies for global HCV eradication. Liver Int 2013; 33 (Suppl. 01) 68-79
  CrossrefPubMedGoogle Scholar
• 64 Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med 2013; 19 (7) 850-858
  CrossrefPubMedGoogle Scholar